Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cumberland Pharmaceuticals (CPIX) EBIT Margin: 2009-2025

Historic EBIT Margin for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Sep 2025 value amounting to -23.70%.

  • Cumberland Pharmaceuticals' EBIT Margin fell 505.00% to -23.70% in Q3 2025 from the same period last year, while for Sep 2025 it was -7.90%, marking a year-over-year increase of 2137.00%. This contributed to the annual value of -16.99% for FY2024, which is 717.00% up from last year.
  • Per Cumberland Pharmaceuticals' latest filing, its EBIT Margin stood at -23.70% for Q3 2025, which was down 243.61% from -6.90% recorded in Q2 2025.
  • In the past 5 years, Cumberland Pharmaceuticals' EBIT Margin registered a high of 11.03% during Q1 2025, and its lowest value of -66.07% during Q4 2023.
  • For the 3-year period, Cumberland Pharmaceuticals' EBIT Margin averaged around -17.21%, with its median value being -17.65% (2024).
  • Per our database at Business Quant, Cumberland Pharmaceuticals' EBIT Margin slumped by 4,110bps in 2023 and then surged by 4,841bps in 2024.
  • Cumberland Pharmaceuticals' EBIT Margin (Quarterly) stood at -52.33% in 2021, then spiked by 2,737bps to -24.97% in 2022, then slumped by 4,110bps to -66.07% in 2023, then spiked by 4,841bps to -17.65% in 2024, then plummeted by 505bps to -23.70% in 2025.
  • Its last three reported values are -23.70% in Q3 2025, -6.90% for Q2 2025, and 11.03% during Q1 2025.